Tru Niagen® Pro 500mg: What the Science Says About NAD+ and Longevity

Dai Tran, PharmD, MBA, B.S.

CEO & Lead Pharmacist, Khang Pharmacy • CA/MN/TX Licensed Pharmacist

Clinical Insights Series • APhA Immunization Certified • 10+ Years Clinical Experience

What Is NAD+ and Why Does It Matter?

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in every living cell. It plays a central role in energy metabolism, DNA repair, and cellular communication. NAD+ levels decline with aging across multiple experimental models, but the extent and consistency of age-related NAD+ decline in humans remain less clearly established and appear to vary by tissue, population, and measurement method. For a full comparison of NAD+ precursor options, see our NAD+ vs NMN vs NR pharmacist evidence review →

What Is Nicotinamide Riboside (NR)?

Tru Niagen® uses a patented form of Vitamin B3 called Nicotinamide Riboside (NR), which serves as a precursor to NAD+. NR has been evaluated in multiple published human clinical trials and has consistently demonstrated the ability to raise NAD+-related biomarkers in the blood. Whether this biochemical target engagement translates to clinical health benefits is an active and ongoing area of research.

What the Clinical Research Shows

Tru Niagen® Pro 500mg contains Niagen® (nicotinamide riboside chloride), an NR ingredient that has been used in published human clinical studies. Key findings from the NR human research literature include:

• Increased NAD+ biomarkers: Multiple human studies have documented that oral NR raises NAD+-related metabolites in a dose-dependent manner. The degree of increase varies by study population, dose, and duration.
• Safety and tolerability: A randomized double-blind placebo-controlled trial (Conze et al., 2019, PMID: 31278280) found that NR at doses of 100, 300, and 1,000 mg/day for 8 weeks produced dose-dependent increases in whole-blood NAD+ with adverse-event rates that did not significantly differ from placebo. ChromaDex involvement and funding is disclosed in the conflict-of-interest statement.
• Cardiovascular-related measures: A small randomized crossover trial (Martens et al., 2018, PMID: 29599478; n=24) found exploratory signals for possible reductions in systolic blood pressure and arterial stiffness with NR 500 mg twice daily for 6 weeks, but the trial was not designed to establish cardiovascular clinical benefit and results require confirmation in larger trials.
• Mitochondrial function — null result: A randomized placebo-controlled trial (Dollerup et al., 2020, PMID: 31710095) in men with obesity and insulin resistance found that NR 2,000 mg/day for 12 weeks increased NAD+-related metabolites but did not improve skeletal-muscle mitochondrial respiration, content, or morphology compared with placebo. This null result is an important part of the NR evidence base.
• Overall: A 2026 PRISMA-guided systematic review (Gallagher & Emmanuel, PMID: 41655607) concluded that NR and NMN reliably show biochemical target engagement but clinical outcomes remain heterogeneous, often null or endpoint-specific, and clinical effectiveness for anti-aging and wellness remains inconclusive.

About Tru Niagen® Pro 500mg

The Pro 500mg formulation delivers 500 mg of Niagen® (patented NR) per capsule. Tru Niagen® is manufactured by ChromaDex, whose NR ingredient has been used in published human pharmacokinetic and intervention studies. Consumers should verify current product label specifications and certifications directly with the manufacturer.

Who May Consider Tru Niagen® Pro?

• Adults interested in discussing NAD+ precursor supplementation with a pharmacist or healthcare professional.
• Individuals who understand that the human research on NR demonstrates consistent biochemical target engagement but that clinical outcome data remain heterogeneous and preliminary.
• People seeking an NR supplement from a manufacturer whose ingredient has been used in published human studies.

Patients with significant medical conditions, those taking prescription medications, or those with cancer or metabolic disease should discuss supplementation with their treating clinician before use. NAD+ precursor supplements should not be used as a substitute for established medical treatment.

Selected Key Studies

1. HUMAN STUDY Trammell SAJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016;7:12948. PMID: 27721479. DOI: 10.1038/ncomms12948.
   Human pharmacokinetic research demonstrating dose-dependent changes in the blood NAD+ metabolome following oral NR administration. NR was supplied by ChromaDex; several authors reported financial relationships with ChromaDex.
2. HUMAN RCT Conze D, Brenner C, Kruger CL. Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Sci Rep. 2019;9(1):9772. PMID: 31278280. DOI: 10.1038/s41598-019-46120-z.
   Eight-week randomized trial (n=140) showing dose-dependent increases in whole-blood NAD+ with 100, 300, and 1,000 mg/day NR; adverse-event rates did not significantly differ from placebo. ChromaDex involvement and funding disclosed in conflict-of-interest statement.
3. HUMAN RCT Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. PMID: 29599478. DOI: 10.1038/s41467-018-03421-7.
   Randomized crossover trial showing increased NAD+ metabolism with NR; exploratory cardiovascular findings require confirmation in larger trials.
4. HUMAN RCT — NULL RESULT Dollerup OL, et al. Nicotinamide riboside does not alter mitochondrial respiration, content or morphology in skeletal muscle from obese and insulin-resistant men. J Physiol. 2020;598(4):731–754. PMID: 31710095. DOI: 10.1113/JP278752.
   NR increased NAD-related metabolites but did not improve skeletal-muscle mitochondrial respiration, content, or morphology compared with placebo.
5. SYSTEMATIC REVIEW Gallagher C, Emmanuel OO. NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Res Rev. 2026;116:103057. PMID: 41655607. DOI: 10.1016/j.arr.2026.103057.
   Systematic review finding consistent biochemical target engagement with oral NR and NMN, while clinical outcomes remained heterogeneous, often null or endpoint-specific; clinical effectiveness for anti-aging and wellness remains inconclusive.

Reviewed by: Dai Tran, PharmD, MBA, B.S. View full bio →

CEO & Lead Pharmacist, Khang Pharmacy • CA/MN/TX Licensed Pharmacist

Clinical Insights Series • APhA Immunization Certified • 10+ Years Clinical Experience

Khang Pharmacy | 2451 S King Rd., Ste A1, San Jose, CA 95122 | (408) 622-8068 | www.khangpharmacy.com